Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Expands By 27.3%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 439,335 shares, a growth of 27.3% from the January 15th total of 345,021 shares. Based on an average daily trading volume, of 174,125 shares, the short-interest ratio is presently 2.5 days. Approximately 1.1% of the shares of the company are short sold. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 174,125 shares, the short-interest ratio is presently 2.5 days.

Institutional Investors Weigh In On MIRA Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in shares of MIRA Pharmaceuticals by 100.0% during the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of MIRA Pharmaceuticals during the fourth quarter valued at approximately $30,000. First American Bank increased its position in MIRA Pharmaceuticals by 20.0% during the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after purchasing an additional 10,000 shares during the period. Two Sigma Investments LP boosted its stake in shares of MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after purchasing an additional 25,816 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in MIRA Pharmaceuticals during the 2nd quarter valued at approximately $26,000. 35.16% of the stock is owned by hedge funds and other institutional investors.

MIRA Pharmaceuticals Trading Up 7.8%

Shares of MIRA Pharmaceuticals stock traded up $0.09 on Tuesday, reaching $1.25. The stock had a trading volume of 188,868 shares, compared to its average volume of 152,552. The business’s 50 day moving average is $1.40 and its two-hundred day moving average is $1.42. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45. The company has a market cap of $52.35 million, a P/E ratio of -0.82 and a beta of 1.80.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Rodman & Renshaw assumed coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating for the company. Wall Street Zen lowered shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, MIRA Pharmaceuticals has an average rating of “Hold”.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.